



Meta-Analysis of Associations of IL1 Receptor Antagonist and Estrogen Receptor Gene Polymorphisms with Systemic Lupus Erythematosus Susceptibility

Li Cai^{1,3}, Jin-wei Zhang^{2,3}, Xing-xin Xue¹, Zhi-gang Wang³, Jia-jia Wang¹, Shai-di Tang¹, Shao-wen Tang¹, Jie Wang^{4,5}, Yun Zhang^{1,6*}, Xian Xia^{3*}

1 Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Jiangning District, Nanjing, Jiangsu, China, **2** Department of Anesthesiology, Affiliated Drum Tower Hospital of Medical College of Nanjing University, Gulou District, Nanjing, Jiangsu, China, **3** Department of Nosocomial Infection Control, General Hospital of Beijing Military Region, Dongcheng District, Beijing, China, **4** State Key Laboratory of Reproductive Medicine, Nanjing Medical University, Jiangning District, Nanjing, Jiangsu, China, **5** Department of General Practice, Kangda College, Nanjing Medical University, Jiangning District, Nanjing, Jiangsu, China, **6** Institute of Epidemiology and Microbiology, Huadong Research Institute for Medicine and Biotechnics, Nanjing, Jiangsu, China

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease that affects a number of different organs and tissues. Interleukin-1 (IL1) and estrogen are considered potential elements in the pathology of SLE. Recently, the variable number of tandem repeats (VNTR) polymorphism in the IL1 receptor antagonist gene (*IL1-RN*) and *PvuII* (rs2234693) and *XbaI* (rs9340799) polymorphisms in the estrogen receptor 1 gene (*ESR1*) have been associated with a predisposition to SLE. However, the evidence for these associations is inconclusive. We therefore conducted a meta-analysis to validate the roles of these polymorphisms in SLE susceptibility. We searched four databases and identified a total of 17 eligible articles comprising 24 studies. The Newcastle-Ottawa quality assessment scale was used to assess the qualities of the selected studies. We assessed the strengths of the associations using odds ratios (ORs) with 95% confidence intervals (95% CIs). Regarding the *IL1-RN* VNTR, the 2 allele significantly increased SLE susceptibility (2 vs. 1: OR = 1.34, 95% CI = 1.03–1.73, $P = 0.03$). The *ESR1 PvuII* CC/CT genotype was also associated with SLE susceptibility (CC/CT vs. TT: OR = 1.25, 95% CI = 1.06–1.47, $P = 0.01$), and the difference was especially pronounced among Asians (CC/CT vs. TT: OR = 1.33, 95% CI = 1.04–1.69, $P = 0.02$). No significant association between the *ESR1 XbaI* polymorphism and SLE susceptibility was observed in the overall analysis. However, a marginally significant association between the GG/GA genotype was found in individuals of Asian descent (GG/GA vs. AA: OR = 1.30, 95% CI = 1.01–1.67, $P = 0.04$). These results indicate that the *IL1-RN* VNTR 2 allele, *ESR1 PvuII* CC/CT genotype and *ESR1 XbaI* GG/GA genotype may increase SLE susceptibility, especially in Asian individuals.

Citation: Cai L, Zhang J-w, Xue X-x, Wang Z-g, Wang J-j, et al. (2014) Meta-Analysis of Associations of IL1 Receptor Antagonist and Estrogen Receptor Gene Polymorphisms with Systemic Lupus Erythematosus Susceptibility. PLoS ONE 9(10): e109712. doi:10.1371/journal.pone.0109712

Editor: Shervin Assasi, University of Texas Health Science Center at Houston, United States of America

Received: March 12, 2014; **Accepted:** September 7, 2014; **Published:** October 6, 2014

Copyright: © 2014 Cai et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All data are included within the paper and its Supporting Information files.

Funding: This study was supported by grants from the National Natural Science Foundation of China (Grant No. 81273146, 81102165). (<http://www.nsfc.gov.cn>) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* Email: zhangyunvip@126.com (YZ); r_summer@163.com (Xian Xia)

These authors contributed equally to this work.

Introduction

Systemic lupus erythematosus (SLE) is an autoimmune disease that affects various organs and tissues, involving the production of a range of autoantibodies against serological, intracellular, nucleic acid and cell surface antigens [1]. Although the mechanisms underlying SLE are not fully understood, genetic, environmental and hormonal factors are all thought to impact on the development of the disease [2].

Cytokines are considered to be potential elements in the pathology of SLE. These include interleukin-1 (IL1), which plays a key regulatory role in initiating and modulating immunologic and inflammatory events [3,4]. Animals with experimental SLE produced increased levels of IL1 throughout the disease course [5]. The IL1 family consists of IL1 α , IL1 β and IL1 receptor

antagonist (IL1-RA) [6]. IL1-RA is an important anti-inflammatory molecule that binds to IL1 receptors in competition with IL1 α and IL1 β , thus inhibiting their activities and modulating a variety of IL1-related immune and inflammatory activities [7]. The IL1-RA gene (*IL1-RN*) has a variable number of tandem repeats (VNTR) polymorphism of 86 base pairs (bp) in intron 2. Five alleles correspond to allele 1 (four repeats), allele 2 (two repeats), allele 3 (five repeats), allele 4 (three repeats) and allele 5 (six repeats), which can be further categorized into a long allele (L: 3–6 repeats) and a short allele (S: 2 repeats). The genotypes are therefore classified as LL, 2L and 2S [8]. Blakemore *et al.* [9] first revealed that the frequency of the *IL1-RN* VNTR 2 allele was increased in SLE patients, since when mounting studies have explored the relationship between the *IL1-RN* VNTR polymor-

phism and SLE susceptibility in different populations; however, the findings have been controversial [10–12].

Estrogen is another underlying element in the pathology of SLE. SLE typically presents in women of childbearing age [13] and its morbidity falls remarkably after the menopause, in line with the decline in endogenous estrogen [14]. In an SLE mouse model, female mice had poorer outcomes than male mice, and estrogens exacerbated, while androgens ameliorated, the disease [15]. One possible mechanism is that physiological concentrations of estrogen could affect the secretion of cytokines such as IL1 [16–18]. However, the roles of estrogen and IL1 in SLE remain unclear. Estrogen acts on target cells through binding to estrogen receptors (ERs). ER α , encoded by the ER 1 gene (*ESR1*), is the main form of ER. Two polymorphisms, *ESR1 PvuII* T/C (rs2234693) and *ESR1 XbaI* A/G (rs9340799), located in the first intron of the *ESR1* gene, have been extensively studied, but the associations between these polymorphisms and SLE susceptibility remain controversial [19,20].

Limited sample sizes and inadequate statistical power mean that the results of studies of the relationships between the *IL1-RN* VNTR, *ESR1 PvuII*, and *ESR1 XbaI* polymorphisms and SLE susceptibility remain conflicting, rather than conclusive [9–12,19–31]. Given the potentially important roles of these three polymorphisms in the pathological process and the increasing numbers of studies in different populations, we performed a meta-analysis to derive a more precise estimation of the associations between the *IL1-RN* VNTR, *ESR1 PvuII*, and *ESR1 XbaI* polymorphisms and SLE susceptibility.

Materials and Methods

Search strategy

We searched the PubMed, Embase, Wanfang and Chinese National Knowledge Infrastructure databases using the search terms: 'systemic lupus erythematosus' or 'SLE', 'polymorphism' or 'allele' or 'genotype', 'interleukin-1 receptor antagonist' or '*IL1-RN*' or 'estrogen receptor' or 'ER'. The literature search was updated on December 2013 and there was no date limit. The results were also supplemented with manual searches of references from the final published articles.

Study selection

The inclusion criteria were: (1) case-control design; (2) studies investigating the relationship between the *IL1-RN* VNTR, *ESR1 PvuII* or *ESR1 XbaI* polymorphisms and SLE susceptibility; (3) studies with sufficient data to provide odds ratios (ORs) and 95% confidence intervals (CIs); and (4) diagnosis of SLE patients performed according to the American College of Rheumatology criteria [32,33]. The exclusion criteria were: (1) studies with overlapping populations; and (2) studies with insufficient data.

Data extraction

The following information was sought from each publication: first author's surname, year of publication, participants' country, ethnicity, sex distribution, genotyping methods, the source of control groups (population-based or hospital-based controls) and matching numbers of genotyped cases and controls. The literature search, eligible study selection and data extraction were carefully conducted independently by two reviewers (Cai and Zhang) and consensus were reached on all items.

Quality appraisal

Two reviewers (Cai and Zhang) independently rated the methodological quality of every included study according to the

Newcastle-Ottawa quality assessment scale [34]. This scale contains nine items (1 point for each) in three parts: selection (four items), comparability (two items) and exposure (three items).

Statistical analysis

Statistical manipulations were conducted using Stata 10.0 (Stata Corporation, College Station, TX, USA). A χ^2 test for goodness of fit was used to test for Hardy-Weinberg equilibrium (HWE) in the control group, with $P < 0.05$ indicating a deviation from HWE. Crude ORs and 95% CIs were used to assess the strengths of the associations between the *IL1-RN* and *ESR1* polymorphisms and SLE susceptibility. The statistical significance of the pooled ORs was determined by the Z test, with $P < 0.05$ considered significant. Statistical heterogeneity among studies was assessed by the Q-test and the I^2 statistic was used to estimate heterogeneity quantitatively [35]. In the absence of heterogeneity ($P > 0.10$ or $I^2 < 50\%$), pooled ORs and 95% CIs were calculated by the fixed-effects model (Mantel-Haenszel method), otherwise the random-effects model (DerSimonian-Laird method) was used. Sensitivity analysis was used to evaluate the stability of the results of the meta-analysis by removing one study at a time to determine the influence of the individual data set on the pooled OR. Potential publication bias was examined by a funnel plot of log OR against its standard error using Begg's test, and the degree of asymmetry was assessed by Egger's unweighted regression asymmetry test. Publication bias may be present if $P < 0.05$ [36].

Results

Study characteristics

A detailed flow chart of the inclusion and exclusion processes is presented in Figure 1. Overall, 86 studies (44 in English and 42 in Chinese) were retrieved based on the search terms. Of these, 69 studies were excluded according to the inclusion and exclusion criteria and 17 eligible articles representing 24 studies were identified (one article was considered as several separate studies if it involved different populations or different target single nucleotide polymorphisms). Eleven studies including 1171 SLE patients and 1834 controls described *IL1-RN* VNTR genotypes, seven studies including 1012 SLE patients and 2442 controls described *ESR1 PvuII* genotypes and six studies including 816 SLE patients and 1478 controls described *ESR1 XbaI* genotypes. The first author's surname, publication year, ethnicity, quality score, sex distribution, frequencies of various genotypes in SLE patients and controls and HWE in controls for each study are listed in Tables 1, 2 and 3. The mean score of the quality appraisal was 6.54. In addition, most of the eligible studies were population-based and polymerase chain reaction was performed in all studies. Genotype distributions in the control populations agreed with HWE in all except seven studies [12,19,22,23,25,29,30].

Quantitative synthesis

Eleven studies including 1171 SLE patients and 1834 controls assessed the relationship between *IL1-RN* VNTR polymorphisms and SLE susceptibility. *IL1-RN* VNTR polymorphism showed no significant association with SLE susceptibility in a dominant model (22/2L vs. LL: OR = 1.11, 95% CI = 0.87–1.40, $P = 0.40$), recessive model (22 vs. LL/2L: OR = 1.32, 95% CI = 0.88–1.97, $P = 0.17$) or additive model (22 vs. LL: OR = 1.32, 95% CI = 0.88–1.98, $P = 0.19$, Table 4). However, a significant association was observed in an allelic contrast model (2 vs. L: OR = 1.34, 95% CI = 1.03–1.73, $P = 0.03$, Figure 2). After excluding the studies in which the genotype distributions in the control groups deviated from HWE, the *IL1-RN* VNTR




Figure 1. Flow diagram of studies included in the meta-analysis.
doi:10.1371/journal.pone.0109712.g001

polymorphism showed no significant association with SLE susceptibility in all genetic models (Table S1). We performed subgroup analyses in Asian and Caucasian populations and found no significant differences in either ethnic subgroup (Table S1).

Seven studies compared the *ESR1 PvuII* polymorphism in SLE patients and controls. Individuals carrying variant genotypes had an increased risk of SLE in the dominant model (CC/CT vs. TT:

OR = 1.25, 95% CI = 1.06–1.47, $P = 0.01$, Figure 3) but not in other genetic models (CC vs. TT/CT: OR = 0.96, 95% CI = 0.79–1.17, $P = 0.71$; CC vs. TT: OR = 1.10, 95% CI = 0.88–1.38, $P = 0.41$; C vs. T: OR = 1.28, 95% CI = 0.95–1.74, $P = 0.11$, Table 4). After excluding the study in which the genotype distribution in the control group deviated from the HWE, *ESR1 PvuII* polymorphism was significantly associated

Table 1. Characteristics and *IL1-RN* VNTR polymorphism genotype distributions in studies included in the meta-analysis.

Author, year	Ethnicity	Quality score ^a	Control		Case				<i>P</i> _{HWE}			
			LL	2L	2	L	2	LL		2L	L	2
Isai 2006 [10]	Taiwan(Asian)	6	–	–	–	142	6	–	–	198	10	–
Lee 2004 [11]	Korean(Asian)	7	109	18	0	236	18	83	10	0	176	10
Parks 2004 [12]	United States(Caucasian)	7	169	18	15	356	48	66	12	8	144	28
Parks 2004 [12]	United States(African-American)	7	69	3	0	141	3	137	6	1	280	8
Jonsen2004 [21]	Sweden(Caucasian)	6	111	75	14	297	103	86	38	14	210	66
Huang 2002 [22]	Taiwan(Asian)	7	96	6	1	198	8	43	8	1	94	10
Zhu 2000 [23]	China(Asian)	5	15	31	4	61	39	26	52	2	104	56
Tjernstrom 1999 [24]	Sweden(Caucasian)	7	–	–	–	339	39	–	–	–	130	32
Heward 1999 [25]	Caucasian(Caucasian)	4	312	7	19	631	45	106	4	6	216	16
Suzuki 1997 [26]	Japan(Asian)	4	–	–	–	418	18	–	–	–	354	38
Blakemore 1994 [9]	England(Caucasian)	7	152	92	17	396	126	39	31	11	109	53

^aThe quality score was determined by using the Newcastle-Ottawa quality assessment scale.

IL1-RN: interleukin-1 receptor antagonist gene; VNTR: variable number of tandem repeats; HWE: Hardy-Weinberg equilibrium.

doi:10.1371/journal.pone.0109712.t001

Table 2. Characteristics and *ESR1 PvuII* polymorphism genotype distributions in studies included in the meta-analysis.

Author, year	Ethnicity	Quality score ^a	Gender (M/F)		Control				Case				<i>P</i> _{HWE}
			Control	Case	TT	TC	CC	T	C	TT	TC	CC	T
Kisiel 2011 [20]	Poland (Caucasian)	6	482/482	14/182	270	467	227	1007	921	44	101	51	189
Wang 2010 [23]	United States(Mixed)	8	0/102	0/46	38	48	15	124	78	9	26	11	44
Lu 2009 [28]	China(Asian)	7	0/157	0/221	83	56	18	222	92	95	92	34	282
Li 2008 [29]	China(Asian)	6	0/200	0/70	86	82	32	254	146	23	39	8	85
Chen 2008 [30]	China(Asian)	5	36/46	6/76	30	31	21	91	73	37	30	15	104
Johansson 2005 [31]	Sweden(Caucasian)	9	180/490	40/220	208	332	130	748	592	83	132	45	298
Lee 2004 [19]	Korean(Asian)	7	0/268	0/137	114	110	44	338	198	46	76	15	106

^aThe quality score was determined by using the Newcastle-Ottawa quality assessment scale.

ESR1: estrogen receptor 1 gene; M: Male; F: Female; HWE: Hardy-Weinberg equilibrium.

doi:10.1371/journal.pone.0109712.t002

Table 3. Characteristics and *ESR1 XbaI* polymorphism genotype distributions in studies included in the meta-analysis.

Author, year	Ethnicity	Quality score ^a	Gender (M/F)		Control				Case				P _{HWE}		
			Control	Case	AA	AG	GG	A	G	AA	AG	GG		A	G
Wang 2010 [23]	United States(Mixed)	8	0/102	0/46	48	44	9	140	62	14	24	8	52	40	0.81
Lu 2009 [28]	China(Asian)	7	0/157	0/221	112	38	7	262	52	138	73	10	349	93	0.12
Li 2008 [29]	China(Asian)	6	0/200	0/70	144	46	10	334	66	46	19	5	111	29	0.02
Chen 2008 [30]	China(Asian)	5	36/46	6/76	45	29	8	119	45	48	31	3	127	37	0.31
Johansson 2005 [31]	Sweden(Caucasian)	9	180/490	40/220	332	281	57	945	395	145	94	21	384	136	0.82
Lee 2004 [19]	Korean(Asian)	7	0/268	0/137	192	62	14	446	90	89	38	10	216	58	<0.01

^aThe quality score was determined by using the Newcastle-Ottawa quality assessment scale.
ESR1: estrogen receptor 1 gene; M: Male; F: Female; HWE: Hardy-Weinberg equilibrium.
doi:10.1371/journal.pone.0109712.t003

with SLE susceptibility in both dominant and allelic contrast models (Table S2). When grouped by ethnicity, a significant association was still observed in the dominant model in the Asian group (CC/CT vs. TT: OR = 1.33, 95% CI = 1.04–1.69, *P* = 0.02, Table S2) but not in the Caucasian group (CC/CT vs. TT: OR = 1.11, 95% CI = 0.88–1.40, *P* = 0.38, Table S2).

Six studies investigated the association between *ESR1 XbaI* polymorphism and SLE susceptibility. No significant relationships were identified for any of the genetic models in the whole study set (GG/GA vs. AA: OR = 1.19, 95% CI = 0.88–1.62, *P* = 0.27; GG vs. AA/GA: OR = 1.08, 95% CI = 0.77–1.51, *P* = 0.67; GG vs. AA: OR = 1.09, 95% CI = 0.77–1.54, *P* = 0.64; G vs. A: OR = 1.15, 95% CI = 0.89–1.49, *P* = 0.27, Table 4). Exclusion of the two studies in which the genotype distributions in the control groups deviated from the HWE had no significant effect on the results (Table S3). However, stratified analysis by ethnicity demonstrated a marginally significant association in the dominant model (GG/GA vs. AA: OR = 1.30, 95% CI = 1.01–1.67, *P* = 0.04, Figure 4, Table S3) in individuals of Asian descent.

Tests of heterogeneity

For *IL1-RN* VNTR, *ESR1 PvuII*, and *ESR1 XbaI*, heterogeneity between studies was observed in the overall analysis of the allelic contrast model (*P*_{heterogeneity} = 0.02, 0.00, 0.03, respectively, Table 4). In addition, heterogeneity was also found for *ESR1 XbaI* in the dominant model (*P*_{heterogeneity} = 0.03). Ethnicity was assessed as a potential source of heterogeneity. Ethnicity (χ^2 = 11.49, df = 2, *P* = 0.003) contributed to the heterogeneity for *ESR1 PvuII*. Ethnicity also contributed to the heterogeneity for the dominant model (χ^2 = 10.00, df = 2, *P* = 0.007) and the allelic contrast model (χ^2 = 8.83, df = 2, *P* = 0.010) for *ESR1 XbaI*.

Sensitivity analysis

Sensitivity analysis revealed that heterogeneity decreased after some studies were removed: Jonsen *et al.* 2004 [21] for *IL1-RN* VNTR (2 vs. L: *P*_{heterogeneity} = 0.08, *I*² = 41.8%); Johansson *et al.* 2005 [31] for *ESR1 XbaI* (G vs. A: *P*_{heterogeneity} = 0.25, *I*² = 26.4%); and Johansson *et al.* 2005 [31] for *ESR1 XbaI* (GG/GA vs. AA: *P*_{heterogeneity} = 0.48, *I*² = 0.0%). The results of the association between *ESR1 PvuII* and SLE susceptibility were not substantially altered.

Publication bias

No publication bias was detected among studies regarding the association between the *IL1-RN* VNTR polymorphism and SLE (*P* = 0.83 for 2 vs. L, Figure 5). Similarly, the results of Egger's and Begg's tests showed no publication bias for the *ESR1 PvuII* or *ESR1 XbaI* polymorphisms in all models.

Discussion

Studies of gene polymorphisms potentially related to SLE have recently attracted growing attention. In the present study, we performed a meta-analysis of the associations between *IL1-RN* VNTR, *ESR1 PvuII*, and *ESR1 XbaI* polymorphisms and SLE susceptibility. The analysis indicated an association between the 2 allele of the VNTR polymorphism in intron 2 of *IL1-RN* and increased SLE susceptibility (2 vs. L: OR = 1.34, 95% CI = 1.03–1.73, *P* = 0.03). There was also an association between *ESR1 PvuII* and SLE in the dominant model (CC/CT vs. TT: OR = 1.25, 95% CI = 1.06–1.47, *P* = 0.01), which was pronounced among Asian individuals (CC/CT vs. TT: OR = 1.33, 95% CI = 1.04–1.69, *P* = 0.02). There was no significant association between the *ESR1 XbaI* polymorphism and SLE suscepti-




Figure 2. Forest plot of the association between SLE susceptibility and *IL1-RN* VNTR polymorphism (2 versus L).
doi:10.1371/journal.pone.0109712.g002

bility in the overall analysis, but the GG/GA genotype was associated with SLE susceptibility in Asians (GG/GA vs. AA: OR = 1.30, 95% CI = 1.01–1.67, $P = 0.04$).

IL1 is a potent pro-inflammatory cytokine in acute and chronic inflammation in SLE [37]. IL1RA is a natural antagonist of IL1

and its anti-inflammatory activity is mediated through several different pathways [38] and investigations found decreased production of IL1RA in active SLE [39]. The *IL1-RN* VNTR 2 allele was associated with increased production of IL1 β *in vitro* [40,41] and the concentration of IL1RA was shown to be

Table 4. Main results of meta-analysis of the association of *IL1-RN* VNTR, *ESR1* PvuII and *ESR1* XbaI polymorphisms with SLE susceptibility.

Gene and Genetic models	Number of study	$P_{\text{heterogeneity}}$	$I^2(\%)$	Type of effect model	ORs (95% CI)	P
<i>IL1-RN</i> VNTR						
Dominant (22/2L vs. LL)	8	0.19	29.3	Fixed	1.11 (0.87–1.40)	0.40
Recessive (22 vs. LL/2L)	7	0.50	0	Fixed	1.32 (0.88–1.97)	0.17
Additive (22 vs. LL)	7	0.46	0	Fixed	1.32 (0.88–1.98)	0.19
Allelic contrast (2 vs. L)	11	0.02	51.4	Random	1.34 (1.03–1.73)	0.03
<i>ESR1</i> PvuII						
Dominant (CC/CT vs. TT)	7	0.10	43.3	Fixed	1.25 (1.06–1.47)	0.01
Recessive (CC vs. TT/CT)	7	0.22	26.8	Fixed	0.96 (0.79–1.17)	0.71
Additive (CC vs. TT)	7	0.11	42.5	Fixed	1.10 (0.88–1.38)	0.41
Allelic contrast (C vs. T)	7	0.00	85.5	Random	1.28 (0.95–1.74)	0.11
<i>ESR1</i> XbaI						
Dominant(GG/GA vs. AA)	6	0.03	58.8	Random	1.19 (0.88–1.62)	0.27
Recessive(GG vs. AA/AG)	6	0.39	6.1	Fixed	1.08 (0.77–1.51)	0.67
Additive(GG vs. AA)	6	0.17	35.1	Fixed	1.09 (0.77–1.54)	0.64
Allelic contrast(G vs. A)	6	0.03	60.4	Random	1.15 (0.89–1.49)	0.27

IL1-RN: Interleukin-1 receptor antagonist gene; VNTR: variable number of tandem repeats; *ESR1*: estrogen receptor 1 gene; OR: odds ratio; CI: confidence interval.
doi:10.1371/journal.pone.0109712.t004




Figure 3. Forest plot of the association between SLE susceptibility and *ESR1* PvuII polymorphism (CC/CT versus TT).
doi:10.1371/journal.pone.0109712.g003




Figure 4. Forest plot of the association between SLE susceptibility and *ESR1* XbaI polymorphism in Asian descent (GG/GA versus AA).
doi:10.1371/journal.pone.0109712.g004




Figure 5. Begg's funnel plot for publication bias test. *IL1-RN* VNTR: 2 versus L.
doi:10.1371/journal.pone.0109712.g005

correlated with IL1 β [42]. Also, this meta-analysis identified carriage of the 2 allele as a risk factor for SLE susceptibility (2 vs. L: OR = 1.34, 95% CI = 1.03–1.73, $P = 0.03$). In support of this, the *IL1-RN* VNTR contains three potential protein-binding sites: an acute phase response element, an interferon α and an interferon β silencer B [43]. The 2 allele of *IL1-RN* VNTR only has 2 repeats. This could affect mRNA length and subsequent protein processing and stability [44], which could in turn affect the production of IL1RA.

Our study also showed that the *ESR1 PvuII* CC/CT and *ESR1 XbaI* GG/GA genotypes could increase susceptibility to SLE. Estrogen can affect both innate and adaptive immune responses in mice [45] and SLE patients [46] through different pathways [47–49], and estrogen receptors are expressed in most immunocompetent cells [50]. Some researchers determined that IL1 β levels were higher during the luteal period compared with the follicular period of the female reproductive cycle, which was consistent with the results of *in vivo* [51–53] and *in vitro* tests [18]. The polymorphisms *PvuII* and *XbaI* are located in intron 1 of *ESR1* but are still able to affect the gene, and thus affect estrogen concentrations. The C allele of *PvuII* can produce a binding site for the B-myb transcription factor, which could enhance the ability to up-regulate downstream receptor structures compared with the T allele [54]. In the present study, SLE susceptibility was associated with the *ESR1 PvuII* C allele but not with *XbaI* in overall analysis. However, we could not rule out the possibility of an association between the *ESR1 XbaI* polymorphism and SLE susceptibility because *PvuII* and *XbaI* are tightly linked [55] and it is difficult to identify which one has a role to play.

Given its multifactorial nature, it is likely that the pathogenesis of SLE may be modulated by age, gender, ethnicity, environmental factors and other variables. We therefore carried out subgroup analysis based on ethnicity. Associations between SLE

susceptibility and the *ESR1 PvuII* C allele and the *ESR1 XbaI* G allele were found in individuals of Asian descent. This may be attributable to genetic heterogeneity among different populations. Consistent with this, ethnicity contributed to the heterogeneity for *ESR1 PvuII* and *ESR1 XbaI*. Moreover, sensitivity analysis revealed that the heterogeneity was reduced by removing Johansson *et al.*'s [31] study, which was the only study in the meta-analysis of the association between *ESR1 XbaI* polymorphism and SLE susceptibility that was based on Caucasians. It is also possible that differences in lifestyle and environmental factors between different populations may interact with genes to affect the pathogenesis of SLE.

This meta-analysis had some inevitable limitations. First, three studies on the *IL1-RN* VNTR polymorphism did not provide genotype data, and the data used to analyze the various genetic models were thus not completely consistent. This may lead to misinterpretation of the association between the *IL1-RN* VNTR polymorphism and SLE susceptibility. Second, although all eligible studies were included in our study, the small sample size and low statistical power (Table S4, S5 and S6) associated with the low incidence of SLE means that there is a possibility of false negative results. We expect more participants being tested in the future to draw a more reliable conclusion. Third, deviation of genotype distributions from HWE in the control populations in some studies may reflect genotyping errors or control selection bias. The results relating to *IL1-RN* VNTR and *ESR1 PvuII* changed when these studies were excluded, suggesting that these results should be interpreted with caution. Fourth, as mentioned above, various factors affect the pathology of SLE; the lack of individual data meant that we only pooled the data based on unadjusted information. Finally, the quality scores were not high for some studies and these studies may have distorted the results.

In conclusion, this meta-analysis indicated that the *IL1-RN* VNTR 2 allele and the *ESR1 PvuII* CC/CT and *ESR1 XbaI*

GG/GA genotypes may increase the susceptibility to SLE, especially in individuals of Asian descent. However, this conclusion should be interpreted cautiously because of the low statistical power and considerable heterogeneity. Also, further functional studies are needed to investigate the functions of these alleles. Well-designed, large studies in different ethnic groups and with more detailed information on age, sex, and age of onset of the disease are needed to validate our results. Studies of gene-environment interactions in relation to *IL1-RN-ESR1* should also be performed to confirm our preliminary findings.

Supporting Information

Table S1 Meta analysis of the association of *IL1-RN VNTR* polymorphism with SLE susceptibility.
(XLS)

Table S2 Meta analysis of the association of *ESR1 PvuII* polymorphism with SLE susceptibility.
(XLS)

References

1. Tsokos GC (2011) Systemic lupus erythematosus. *N Engl J Med* 365: 2110–2121.
2. D'Cruz DP, Khamashta MA, Hughes GR (2007) Systemic lupus erythematosus. *Lancet* 369: 587–596.
3. Yap DY, Lai KN (2013) The role of cytokines in the pathogenesis of systemic lupus erythematosus - from bench to bedside. *Nephrology (Carlton)* 18: 243–255.
4. Boswell JM, Yui MA, Burt DW, Kelley VE (1988) Increased tumor necrosis factor and IL-1 beta gene expression in the kidneys of mice with lupus nephritis. *J Immunol* 141: 3050–3054.
5. Segal R, Bermas BL, Dayan M, Kalush F, Shearer GM, et al. (1997) Kinetics of cytokine production in experimental systemic lupus erythematosus: involvement of T helper cell 1/T helper cell 2-type cytokines in disease. *J Immunol* 158: 3009–3016.
6. Smith DE, Renshaw BR, Ketchum RR, Kubin M, Garka KE, et al. (2000) Four new members expand the interleukin-1 superfamily. *J Biol Chem* 275: 1169–1175.
7. Dinarello CA (1998) Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. *Int Rev Immunol* 16: 457–499.
8. Vamvakopoulos JE, Taylor CJ, Morris-Stiff GJ, Green C, Metcalfe S (2002) The interleukin-1 receptor antagonist gene: a single-copy variant of the intron 2 variable number tandem repeat (VNTR) polymorphism. *Eur J Immunogenet* 29: 337–340.
9. Blakemore AI, Tarlow JK, Cork MJ, Gordon C, Emery P, et al. (1994) Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus. *Arthritis Rheum* 37: 1380–1385.
10. Tsai LJ, Lan JL, Lin CY, Hsiao SH, Tsai LM, et al. (2006) The different expression patterns of interleukin-1 receptor antagonist in systemic lupus erythematosus. *Tissue Antigens* 68: 493–501.
11. Lee YH, Kim HJ, Rho YH, Choi SJ, Ji JD, et al. (2004) Interleukin-1 receptor antagonist gene polymorphism and rheumatoid arthritis. *Rheumatol Int* 24: 133–136.
12. Parks CG, Cooper GS, Dooley MA, Treadwell EL, St Clair EW, et al. (2004) Systemic lupus erythematosus and genetic variation in the interleukin 1 gene cluster: a population based study in the southeastern United States. *Ann Rheum Dis* 63: 91–94.
13. Ansar Ahmed S, Penhale WJ, Talal N (1985) Sex hormones, immune responses, and autoimmune diseases. Mechanisms of sex hormone action. *Am J Pathol* 121: 531–551.
14. Tucker LB, Menon S, Schaller JG, Isenberg DA (1995) Adult- and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology, and outcome. *Br J Rheumatol* 34: 866–872.
15. Roubinian JR, Talal N, Greenspan JS, Goodman JR, Siiteri PK (1978) Effect of castration and sex hormone treatment on survival, anti-nucleic acid antibodies, and glomerulonephritis in NZB/NZW F1 mice. *J Exp Med* 147: 1568–1583.
16. Yuan Y, Shimizu I, Shen M, Aoyagi E, Takenaka H, et al. (2008) Effects of estradiol and progesterone on the proinflammatory cytokine production by mononuclear cells from patients with chronic hepatitis C. *World J Gastroenterol* 14: 2200–2207.
17. Cunningham M, Gilkeson G (2011) Estrogen receptors in immunity and autoimmunity. *Clin Rev Allergy Immunol* 40: 66–73.
18. Kim C, Cadet P (2010) Environmental toxin 4-nonylphenol and autoimmune diseases: using DNA microarray to examine genetic markers of cytokine expression. *Arch Med Sci* 6: 321–327.
19. Lee YJ, Shin KS, Kang SW, Lee CK, Yoo B, et al. (2004) Association of the oestrogen receptor alpha gene polymorphisms with disease onset in systemic lupus erythematosus. *Ann Rheum Dis* 63: 1244–1249.
20. Kisiel BM, Kosinska J, Wierzbowska M, Rutkowska-Sak L, Musiej-Nowakowska E, et al. (2011) Differential association of juvenile and adult systemic lupus erythematosus with genetic variants of oestrogen receptors alpha and beta. *Lupus* 20: 85–89.
21. Jonsen A, Bengtsson AA, Sturfelt G, Truedsson L (2004) Analysis of HLA DR, HLA DQ, C4A, Fc gammaRIIa, Fc gammaRIIIa, MBL, and IL-1Ra allelic variants in Caucasian systemic lupus erythematosus patients suggests an effect of the combined Fc gammaRIIa R/R and IL-1Ra 2/2 genotypes on disease susceptibility. *Arthritis Res Ther* 6: R557–562.
22. Huang CM, Wu MC, Wu JY, Tsai FJ (2002) Interleukin-1 receptor antagonist gene polymorphism in Chinese patients with systemic lupus erythematosus. *Clin Rheumatol* 21: 255–257.
23. Zhu W, Xie HF, Shi W, Liu ZR (2000) Interleukin-1 receptor antagonist gene polymorphism in patients with systemic lupus erythematosus. *Chin J Dermatol* 33: 35.
24. Tjernstrom F, Hellmer G, Nived O, Truedsson L, Sturfelt G (1999) Synergetic effect between interleukin-1 receptor antagonist allele (IL1RN*2) and MHC class II (DR17,DQ2) in determining susceptibility to systemic lupus erythematosus. *Lupus* 8: 103–108.
25. Heward J, Allahabadia A, Gordon C, Sheppard MC, Barnett AH, et al. (1999) The interleukin-1 receptor antagonist gene shows no allelic association with three autoimmune diseases. *Thyroid* 9: 627–628.
26. Suzuki H, Matsui Y, Kashiwagi H (1997) Interleukin-1 receptor antagonist gene polymorphism in Japanese patients with systemic lupus erythematosus. *Arthritis Rheum* 40: 389–390.
27. Wang J, Nuite M, McAlindon TE (2010) Association of estrogen and aromatase gene polymorphisms with systemic lupus erythematosus. *Lupus* 19: 734–740.
28. Lu ZM, Wang ZE, Wu CX, Wang CY, Zhang BC, et al. (2009) Association of Estrogen Receptor α Gene Polymorphisms with Cytokine Genes Expression in Systemic Lupus Erythematosus. *Croatian Medical Journal* 50: 117–123.
29. Li F, Che ZX, Liu YQ, Fu HL, Wang ZE, et al. (2008) Association between estrogen receptor α gene polymorphisms and systemic lupus erythematosus in Chinese women. *Chin J Clinical Laboratory Science* 26: 112–114.
30. Chen H, Fan Y, Men JL (2008) Relationship between estrogen receptor gene polymorphisms and SLE. *Chin J Dermatol* 41: 46–48.
31. Johansson M, Arlestig L, Moller B, Smedby T, Rantapaa-Dahlqvist S (2005) Oestrogen receptor {alpha} gene polymorphisms in systemic lupus erythematosus. *Ann Rheum Dis* 64: 1611–1617.
32. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, et al. (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 25: 1271–1277.
33. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 40: 1725.
34. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, et al. Home>Our Research>Research Programs>Clinical Epidemiology>The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses [Web page]. Ottawa, ON: Ottawa Hospital Research Institute; n.d. [Available online at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp; Accessed 2012 February 10].
35. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. *BMJ* 327: 557–560.

Table S3 Meta analysis of the association of *ESR1 XbaI* polymorphism with SLE susceptibility.
(XLS)

Table S4 The statistical power of *IL1-RN VNTR* 2 allele in studied included in the meta-analysis.
(XLS)

Table S5 The statistical power of *ESR1 PvuII* CC/CT genotypes in studied included in the meta-analysis.
(XLS)

Table S6 The statistical power of *ESR1 XbaI* GG/GA genotypes in studied included in the meta-analysis.
(XLS)

Author Contributions

Conceived and designed the experiments: X. Xia YZ. Performed the experiments: LC JWZ Jia-jia Wang. Analyzed the data: LC JWZ. Contributed reagents/materials/analysis tools: X. Xue ZGW Shao-wen Tang Jie Wang. Wrote the paper: LC JWZ Shai-di Tang.

36. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. *BMJ* 315: 629–634.
37. Rus V, Atamas SP, Shustova V, Luzina IG, Selaru F, et al. (2002) Expression of cytokine- and chemokine-related genes in peripheral blood mononuclear cells from lupus patients by cDNA array. *Clin Immunol* 102: 283–290.
38. Garat C, Arend WP (2003) Intracellular IL-1Ra type 1 inhibits IL-1-induced IL-6 and IL-8 production in Caco-2 intestinal epithelial cells through inhibition of p38 mitogen-activated protein kinase and NF-kappaB pathways. *Cytokine* 23: 31–40.
39. Hsieh SC, Tsai CY, Sun KH, Tsai YY, Tsai ST, et al. (1995) Defective spontaneous and bacterial lipopolysaccharide-stimulated production of interleukin-1 receptor antagonist by polymorphonuclear neutrophils of patients with active systemic lupus erythematosus. *Br J Rheumatol* 34: 107–112.
40. Danis VA, Millington M, Hyland VJ, Grennan D (1995) Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. *Clin Exp Immunol* 99: 303–310.
41. Santtila S, Savinainen K, Hurme M (1998) Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1beta production in vitro. *Scand J Immunol* 47: 195–198.
42. Vamvakopoulos J, Green C, Metcalfe S (2002) Genetic control of IL-1beta bioactivity through differential regulation of the IL-1 receptor antagonist. *Eur J Immunol* 32: 2988–2996.
43. Tarlow JK, Blakemore AI, Lennard A, Solari R, Hughes HN, et al. (1993) Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. *Hum Genet* 91: 403–404.
44. Korthagen NM, van Moersel CH, Kazemier KM, Ruven HJ, Grutters JC (2012) IL1RN genetic variations and risk of IPF: a meta-analysis and mRNA expression study. *Immunogenetics* 64: 371–377.
45. Nilsson N, Carlsten H (1994) Estrogen induces suppression of natural killer cell cytotoxicity and augmentation of polyclonal B cell activation. *Cell Immunol* 158: 131–139.
46. Kanda N, Tsuchida T, Tamaki K (1999) Estrogen enhancement of anti-double-stranded DNA antibody and immunoglobulin G production in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. *Arthritis Rheum* 42: 328–337.
47. Paharkova-Vatchkova V, Maldonado R, Kovats S (2004) Estrogen preferentially promotes the differentiation of CD11c+ CD11b(intermediate) dendritic cells from bone marrow precursors. *J Immunol* 172: 1426–1436.
48. Suzuki T, Shimizu T, Yu HP, Hsieh YC, Choudhry MA, et al. (2007) Salutary effects of 17beta-estradiol on T-cell signaling and cytokine production after trauma-hemorrhage are mediated primarily via estrogen receptor-alpha. *Am J Physiol Cell Physiol* 292: C2103–2111.
49. Cohen JH, Danel L, Cordier G, Saez S, Revillard JP (1983) Sex steroid receptors in peripheral T cells: absence of androgen receptors and restriction of estrogen receptors to OKT8-positive cells. *J Immunol* 131: 2767–2771.
50. Speirs V, Kerin MJ, Newton CJ, Walton DS, Green AR, et al. (1999) Evidence for transcriptional activation of ERalpha by IL-1beta in breast cancer cells. *Int J Oncol* 15: 1251–1254.
51. Bouman A, Moes H, Heineman MJ, de Leij LF, Faas MM (2001) The immune response during the luteal phase of the ovarian cycle: increasing sensitivity of human monocytes to endotoxin. *Fertil Steril* 76: 555–559.
52. Cannon JG, Dinarello CA (1985) Increased plasma interleukin-1 activity in women after ovulation. *Science* 227: 1247–1249.
53. Polan ML, Loukides JA, Honig J (1994) Interleukin-1 in human ovarian cells and in peripheral blood monocytes increases during the luteal phase: evidence for a midcycle surge in the human. *Am J Obstet Gynecol* 170: 1000–1006; discussion 1006–1007.
54. Herrington DM, Howard TD, Brosnihan KB, McDonnell DP, Li X, et al. (2002) Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. *Circulation* 105: 1879–1882.
55. Liu ZH, Cheng ZH, Gong RJ, Liu H, Liu D, et al. (2002) Sex differences in estrogen receptor gene polymorphism and its association with lupus nephritis in Chinese. *Nephron* 90: 174–180.

© 2014 Cai et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License:

<http://creativecommons.org/licenses/by/4.0/> (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.